β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis

Zhou, Y., Cui, G., Xu, H., Chun, J., Yang, D. Y., Zhang, Z., Yang, L., Wang, J., Wan, M., Calvisi, D. F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05958-y · Cited by 25

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma

Manfredi, G. F., Celsa, C., John, C., Jones, C., Acuti, N., Scheiner, B., Fulgenzi, C. A. M., Korolewicz, J., Pinter, M., Gennari, A., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291553 · Cited by 30

Nanomedicines for reversing immunosuppressive microenvironment of hepatocellular carcinoma

Pan, X., Ni, S., & Hu, K. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122481 · Cited by 26

LOXL4 Shuttled by Tumor Cells–derived Extracellular Vesicles Promotes Immune Escape in Hepatocellular Carcinoma by Activating the STAT1/PD-L1 Axis

Zhao, L., Pei, R., Ding, Y., Su, Z., Li, D., Zhu, S., Xu, L., Zhao, H., & Zhou, W. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000496 · Cited by 24

Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies

Lozano, T., Chocarro, S., Martín-Otal, C., Lasarte-Cía, A., del Valle, C., Gorraiz, M., Sarrión, P., de Galarreta, M. R., Lujambio, A., Hervás‐Stubbs, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02990 · Cited by 24

Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers

Lindblad, K. E., de Galarreta, M. R., & Lujambio, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642958 · Cited by 25

NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice

McVey, J. C., Green, B. L., Ruf, B., McCallen, J., Wabitsch, S., Subramanyam, V., Diggs, L. P., Heinrich, B., Greten, T. F., & Ma, C. (2022) · iScience · doi:10.1016/j.isci.2022.103847 · Cited by 26

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma

Brackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 29

Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine

Bakrania, A. K., To, J. C., Zheng, G., & Bhat, M. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.07.012 · Cited by 26

Wnt/β-catenin signaling pathway in liver biology and tumorigenesis

Matsumoto, S., & Kikuchi, A. (2024) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-024-00858-7 · Cited by 26

Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers

Kwee, S. A., & Tiirikainen, M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.124 · Cited by 24

Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma

Sun, B., Wang, Z.-T., Chen, K.-Z., Song, Y., Wu, J.-F., Zhang, D., Sun, G.-Q., Zhou, J., Fan, J., Hu, B., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02079-z · Cited by 23

Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model

Fournier, C., Mercey-Ressejac, M., Dérangère, V., Kadi, A. A., Rageot, D., Charrat, C., Leroy, A., Vollaire, J., Josserand, V., Escudé, M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2024.105543 · Cited by 27

Maprotiline Suppresses Cholesterol Biosynthesis and Hepatocellular Carcinoma Progression Through Direct Targeting of CRABP1

Zheng, C., Zhu, Y., Liu, Q., Luo, T., & Xu, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.689767 · Cited by 23

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

Machairas, N., Tsilimigras, D. I., & Pawlik, T. M. (2022) · Cancers · doi:10.3390/cancers14082018 · Cited by 24

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

Tella, S. H., Kommalapati, A., Mahipal, A., & Jin, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10061304 · Cited by 23

Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling

Chen, T., Yuan, Z., Lei, Z., Duan, J., Xue, J., Lu, T., Yan, G., Zhang, L., Liu, Y., Li, Q., et al. (2022) · Theranostics · doi:10.7150/thno.75936 · Cited by 24

Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

Ochoa, M. C., Sánchez‐Gregorio, S., de Andrea, C. E., Garasa, S., Álvarez, M., Olivera, I., Glez‐Vaz, J., Luri‐Rey, C., Etxeberría, I., Cirella, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101009 · Cited by 24

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab

Wu, M. C., Fulgenzi, C. A. M., D’Alessio, A., Cortellini, A., Celsa, C., Manfredi, G. F., Stefanini, B., Wu, L. Y., Huang, Y., Saeed, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101232 · Cited by 22

WNT–β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials

Lehrich, B. M., & Monga, S. P. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01127-y · Cited by 27

Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma

Oversoe, S. K., Clement, M. S., Weber, B., Grønbæk, H., Hamilton-Dutoit, S. J., Sørensen, B. S., & Kelsen, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08103-0 · Cited by 22

Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma

Huang, A., Zhang, X., & Zhou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00348-y · Cited by 23

CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis

Huang, Y., Wu, L., Sun, Y., Li, J., Mao, N., Yang, Y. A., Zhao, M., & Ren, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18215 · Cited by 22

Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma

Tamai, Y., Fujiwara, N., Tanaka, T., Mizuno, S., & Nakagawa, H. (2023) · Cancers · doi:10.3390/cancers15205072 · Cited by 21

Lipid Nanovesicle Platforms for Hepatocellular Carcinoma Precision Medicine Therapeutics: Progress and Perspectives

Lehrich, B. M., & Delgado, E. R. (2024) · Organogenesis · doi:10.1080/15476278.2024.2313696 · Cited by 24

Exploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review

Idrissi, Y. A., Rajabi, M. R., Beumer, J. H., Monga, S. P., & Saeed, A. (2024) · Cancer Control · doi:10.1177/10732748241293680 · Cited by 23

Mouse Models of Oncoimmunology in Hepatocellular Carcinoma

Bresnahan, E. R., Lindblad, K. E., de Galarreta, M. R., & Lujambio, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2923 · Cited by 22

The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer

Liu, C., Qifeng, J., & Shaolei, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01117-7 · Cited by 22

Elucidating the role of S100A10 in CD8+ T cell exhaustion and HCC immune escape via the cPLA2 and 5-LOX axis

Wang, G., Shen, X., Jin, W., Song, C., Dong, M., Zhou, Z., & Wang, X. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06895-0 · Cited by 22

Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC

Lehrich, B. M., Tao, J., Liu, S., Hirsch, T. Z., Yasaka, T. M., Cao, C., Delgado, E. R., Guan, X., Lu, S., Pan, L., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101186 · Cited by 23

Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches

Eghbali, S. Z., & Heumann, T. R. (2025) · Cancers · doi:10.3390/cancers17020236 · Cited by 22

Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells

Zhu, G., Tang, Z., Chu, T.-H., Wang, B., Chen, S., Tao, C., Cai, J., Yang, R., Qu, W., Wang, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02118-2 · Cited by 23

TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak

Rozalén, C., Sangrador, I., Avalle, S., Blasco-Benito, S., Tzortzi, P., Sanz‐Flores, M., Palomeque, J. Á., Torren-Duran, P., Dalmau, M., Brunel, H., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.015 · Cited by 21

USP9X promotes the progression of hepatocellular carcinoma by regulating beta-catenin

Chen, M., Li, Z., Sun, Z., & Ma, M. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02199-2 · Cited by 21

miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53 pathway

Gu, J., Han, T., Sun, L., Yan, A., & Jiang, X. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1743910 · Cited by 21

Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Lin, Z., Lu, D., Wei, X., Wang, J., & Xu, X. (2020) · PubMed Central · Cited by 21

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

Huang, Q., Lei, Y., Li, X., Guo, F., & Liu, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580140 · Cited by 22

Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?

Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19

Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer

Feng, M., Wang, F., Liu, X., Hao, T., Zhang, N., Deng, M., Pan, Y., & Kong, R. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0019 · Cited by 23

New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma

Kawamura, E., Matsubara, T., & Kawada, N. (2023) · Cancers · doi:10.3390/cancers15153993 · Cited by 25

Histone methyltransferase KMT5C drives liver cancer progression and directs therapeutic response to PARP inhibitors

Yu, T., Wang, F., Li, S., Guo, W., Li, Q., Qian, Y., Li, L., Zhao, H., Zhang, Y., Gao, W., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000559 · Cited by 21

Combating drug resistance in hepatocellular carcinoma: No awareness today, no action tomorrow

Jing, F., Li, X., Jiang, H., Sun, J., & Guo, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115561 · Cited by 21

Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Dyhl-Polk, A., Mikkelsen, M. K., Ladekarl, M. B., & Nielsen, D. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122662 · Cited by 21

Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

Désert, R., Giannone, F., Saviano, A., Hoshida, Y., Heikenwälder, M. F., Nahon, P., & Baumert, T. F. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00018-y · Cited by 23

Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors

Gasparotto, D., Sbaraglia, M., Rossi, S., Baldazzi, D., Brenca, M., Mondello, A., Nardi, F., Racanelli, D., Cacciatore, M., Tos, A. P. D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142560 · Cited by 20

TRIM36 inhibits tumorigenesis through the Wnt/β-catenin pathway and promotes caspase-dependent apoptosis in hepatocellular carcinoma

Tong, Q., Yi, M., Kong, P., Xu, L. S., Huang, W., Niu, Y., Gan, X., Zhan, H., Tian, R., & Yan, D. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02692-x · Cited by 23

Two Distinct Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations

Aoki, T., Nishida, N., Kurebayashi, Y., Sakai, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Ida, H., Ueshima, K., et al. (2023) · Liver Cancer · doi:10.1159/000533818 · Cited by 20

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy

Cao, J., Zhang, Z., Zhou, L., Luo, M., Li, L., Li, B., Nice, E. C., He, W., Zheng, S., & Huang, C. (2023) · MedComm · doi:10.1002/mco2.427 · Cited by 19

Joining the dots for better liver cancer treatment

Chan, L., & Ng, I. O. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0238-3 · Cited by 19

New systemic agents for hepatocellular carcinoma: an update 2020

von Felden, J. (2020) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000626 · Cited by 20

Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies

Argemí, J., Ponz‐Sarvisé, M., & Sangro, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.002 · Cited by 19

Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate β-catenin in vitro and in vivo

Li, W., Pei, S., Zhang, X., Qi, D., Zhang, W., Dou, Y., Yang, R., Yao, X., Zhang, Z., Xie, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174886 · Cited by 19

Cancer germline antigens and tumor-agnostic CD8+ T cell evasion

Kortleve, D., Coelho, R. M. L., Hammerl, D., & Debets, R. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.03.006 · Cited by 20

The Tumor Microenvironment of Hepatocellular Carcinoma: Untying an Intricate Immunological Network

Volponi, C., Gazzillo, A., & Bonavita, E. (2022) · Cancers · doi:10.3390/cancers14246151 · Cited by 20

Fueling HCC Dynamics: Interplay Between Tumor Microenvironment and Tumor Initiating Cells

Huang, H., Tsui, Y., & Ng, I. O. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.007 · Cited by 19

Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors

Abenavoli, L., Montori, M., Svegliati‐Baroni, G., Argenziano, M. E., Giorgi, F., Scarlata, G. G. M., Ponziani, F. R., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59081427 · Cited by 21

Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents

Nishida, N., & Kudo, M. (2023) · Liver Cancer · doi:10.1159/000534443 · Cited by 19

BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment

Busche, S., John, K., Wandrer, F., Vondran, F. W. R., Lehmann, U., Wedemeyer, H. H., Eßmann, F., Schulze‐Osthoff, K., & Bantel, H. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04020-z · Cited by 19

Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors

Sun, L., Liu, Y., Guo, X., Cui, T., Wu, C., Tao, J., Cheng, C., Chu, Q., Ji, C., Li, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49573-7 · Cited by 18

Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy

Passelli, K., Repáraz, D., Kinj, R., & Herrera, F. G. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae100 · Cited by 18

Spatial‒temporal heterogeneities of liver cancer and the discovery of the invasive zone

Yan, J.-Y., Jiang, Z.-F., Zhang, S., Yu, Q.-C., Lu, Y.-J., Miao, R.-Z., Tang, Z.-Y., Fan, J., Wu, L., Dan, D.-D. G., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70224 · Cited by 18

Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography

Cassol-Brunner, F., Portal, L. F., Richelme, S., Dupont, M., Boursier, Y., Arechederra, M., Auphan‐Anezin, N., Chasson, L., Laprie, C., Fernandez-Sauze, S., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.015 · Cited by 18

Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β‐catenin signaling and tumor growth

Azbazdar, Y., Demirci, Y., Heger, G., Ipekgil, D., Karabicici, M., & Özhan, G. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13520 · Cited by 17

Novel immunotherapeutics against LGR5 to target multiple cancer types

Chen, H., Mueller, N., Stott, K. M., Kapeni, C., Rivers, E., Sauer, C. M., Beke, F., Walsh, S. J., Ashman, N., O’Brien, L. M., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00121-2 · Cited by 19

The immune microenvironment of steatotic hepatocellular carcinoma: Current findings and future prospects

Cheu, J. W., & Wong, C. C. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000516 · Cited by 19

Application of Immunotherapy in Hepatocellular Carcinoma

Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.699060 · Cited by 17

Hallmarks of liver cancer: Therapeutic implications

Llovet, J. M., Pinyol, R., Affò, S., Yarchoan, M. M., Gores, G. J., Kelley, R. K., Lowe, S. W., Sia, D., & Villanueva, A. (2026) · Cell · doi:10.1016/j.cell.2026.03.001 · Cited by 19

Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma

Wu, H., Xu, X., Zhu, J., Wang, M.-D., Li, C. R., Liang, L., Xing, H., Wu, M., Shen, F., Huang, D., et al. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.695635 · Cited by 17

Organoids as research models for hepatocellular carcinoma

Yu, J. H., & Ma, S. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112987 · Cited by 16

The Emerging Role of Ferroptosis in Liver Cancers

Casini, A., Leone, S., Vaccaro, R., Vivacqua, G., Ceci, L., Pannarale, L., Franchitto, A., Onori, P., Gaudio, E., & Mancinelli, R. (2022) · Life · doi:10.3390/life12122128 · Cited by 17

An anoikis-based signature for predicting prognosis in hepatocellular carcinoma with machine learning

Zhang, G., Weiwei, Z., Yun, W., Guangying, C., Zhang, Y., & Yu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1096472 · Cited by 17

Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma

Nishida, N., Aoki, T., Morita, M., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15082379 · Cited by 17

An overview of mouse models of hepatocellular carcinoma

Zheng, H., Xue, H., & Yun, W.-J. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00524-9 · Cited by 19

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma

Carloni, R., Sabbioni, S., Rizzo, A., Ricci, A. D., Palloni, A., Petrarota, C., Cusmai, A., Tavolari, S., Gadaleta‐Caldarola, G., & Brandi, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s390963 · Cited by 18

The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma

Kou, L., Xie, X., Chen, X., Li, B., Li, J., & Li, Y. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03568-3 · Cited by 18

Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma

Heinrich, S., Castven, D., Galle, P. R., & Marquardt, J. U. (2020) · Cancers · doi:10.3390/cancers12092495 · Cited by 18

The head and neck cancer genome in the era of immunotherapy

Wijetunga, N. A., Yu, Y., Morris, L. G. T., Lee, N. Y., & Riaz, N. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105040 · Cited by 17

Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems

Marı́n, J. J. G., Romero, M. R., Herráez, E., Asensio, M., Ortiz-Rivero, S., Sánchez-Martín, A., Fabris, L., & Briz, Ó. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1735631 · Cited by 18

Targeting protein kinases benefits cancer immunotherapy

Zhang, Z., Bu, L., Luo, J., & Guo, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188738 · Cited by 18

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Lindblad, K. E., Donné, R., Liebling, I., Bárcena‐Varela, M., Lozano, A., de Galarreta, M. R., Dhainaut, M., Param, N. J., Giotti, B., Cappuyns, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1215 · Cited by 17

Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions

Ruan, L., & Wang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530541 · Cited by 16

Glucose starvation mimetic aldometanib removes immune barriers permitting mice with hepatocellular carcinoma to live to normal ages

Hu, H.-H., Wang, X., Lan, B., Cheng, H., Wen, H., Chen, F., Wu, J., Li, M., Chen, J., Zhang, J., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01195-4 · Cited by 16

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review

Reiter, F. P., Khaled, N. B., Ye, L., Zhang, C., Seidensticker, M., den Winkel, M. O., Denk, G., Geier, A., & Toni, E. N. D. (2021) · Digestive Diseases · doi:10.1159/000520095 · Cited by 17

CSTF2 Promotes Hepatocarcinogenesis and Hepatocellular Carcinoma Progression via Aerobic Glycolysis

Chen, Z., Hao, W., Tang, J., Gao, W., & Xu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897804 · Cited by 16

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma

Peng, X., Gong, C., Zhang, W., & Zhou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091088 · Cited by 16

Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review

Wang, H., Qian, Y., Dong, H., & Cong, W. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-527 · Cited by 19

Clinico‐histological and molecular features of hepatocellular carcinoma from nonalcoholic fatty liver disease

Fujiwara, N., & Nakagawa, H. (2023) · Cancer Science · doi:10.1111/cas.15925 · Cited by 14

BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights

Vaziri, F., Setayesh, T., Hu, Y. C., Ravindran, R. K., Wei, D., & Wan, Y. Y. (2024) · Advanced Science · doi:10.1002/advs.202308242 · Cited by 15

WDR20 prevents hepatocellular carcinoma senescence by orchestrating the simultaneous USP12/46-mediated deubiquitination of c-Myc

Li, J., Qi, X., Lai, M., Zhou, J., Yuan, M., You, J., Liu, Q., Pan, J., Zhao, L., Ying, M., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2407904121 · Cited by 17

Biomedical engineering targeting cancer stem cells to reinforce cancer therapy

Sun, S., Yang, N., Pei, Z., Gong, F., & Cheng, L. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216494 · Cited by 16

Engineering nanotheranostic strategies for liver cancer

Cao, L., Zhu, Y., Wu, Z., Wang, G., & Cheng, H. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1213 · Cited by 16

An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment

Wang, X., Su, W., Tang, D., Jing, J., Xiong, J., Deng, Y., Liu, H., Ma, W., Liu, Z., & Zhang, Q. (2021) · Cancers · doi:10.3390/cancers13215342 · Cited by 17

Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma

Gao, Q., Liu, H., Xu, Y.-Q., Zhang, L., Liu, Y., Ren, Q., Sheng, J., & Zhang, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02294-z · Cited by 16

Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT

Liao, H., Jiang, H., Chen, Y., Duan, T., Yang, T., Han, M., Xue, Z., Shi, F., Yuan, K., Bashir, M. R., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11505-4 · Cited by 16

Analyses of Transcriptomics Cell Signalling for Pre-Screening Applications in the Integrated Approach for Testing and Assessment of Non-Genotoxic Carcinogens

Oku, Y., Madia, F., Lau, P., Paparella, M., McGovern, T. J., Luijten, M., & Jacobs, M. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112718 · Cited by 18

Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade

Lotsberg, M. L., Rayford, A. J., Thiery, J. P., Belleggia, G., Peters, S. D., Lorens, J. B., Chouaı̈b, S., Terry, S., & Engelsen, A. S. T. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.41 · Cited by 17

The Tumor Microenvironment in Hepatocellular Carcinoma

Nagaoka, K., Tanaka, Y., & Hino, O. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_66 · Cited by 16

Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways

Seliger, B., & Massa, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883639 · Cited by 15

Deciphering the immune heterogeneity dominated by natural killer cells with prognostic and therapeutic implications in hepatocellular carcinoma

Guo, C., Tang, Y., Li, Q., Yang, Z., Guo, Y., Chen, C., & Zhang, Y. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106872 · Cited by 16

HCV and HCC Tango—Deciphering the Intricate Dance of Disease: A Review Article

Milošević, I., Todorović, N., Filipović, A., Simić, J., Marković, M., Stevanović, O., Malinić, J., Katanić, N., Mitrović, N., & Nikolic, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216048 · Cited by 16

Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation

Berraondo, P., Ochoa, M. C., Olivera, I., & Melero, I. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0696 · Cited by 34

Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers

Kwee, S. A., & Tiirikainen, M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2020.124 · Cited by 24

IDDF2024-ABS-0079 Targeting STING pathway as a therapeutic strategy against β-catenin driven immune escape and resistance to anti-PD1 therapy in hepatocellular carcinoma

Zhang, Q., Bi, J., Yeung, O. W. H., Ding, T., Chan, W.-L., Zhu, Y., Liu, J., Ng, T., Ching, Y. P., & Man, K. (2024) · doi:10.1136/gutjnl-2024-iddf.168

Su1460 - Oncoprotein RBMY Facilitates the Development and Metastasis of Hepatocellular Carcinoma

Ni, Y., Chua, H., & Chang, M. (2018) · Gastroenterology · doi:10.1016/s0016-5085(18)33821-6

Extracellular Vesicle‐Based Therapeutic Targeting of β‐Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer

Matsuda, A., Ishiguro, K., Yan, I. K., & Patel, T. C. (2019) · Hepatology Communications · doi:10.1002/hep4.1311 · Cited by 60